• 1. Antibiotic removal by metal–organic framework and 2D nanomaterial based polyetherimide mixed matrix membranes using a membrane bioreactor
  Amol Vijay Sonawane,Z. V. P. Murthy Environ. Sci.: Water Res. Technol. 2023 9 86
• 2. Nanomaterial-based drug delivery systems as promising carriers for patients with COVID-19
  M. Abd Elkodous,S. O. Olojede,Mahmoud Morsi,Gharieb S. El-Sayyad RSC Adv. 2021 11 26463
• 3. Comparative assessment of RNA-dependent RNA polymerase (RdRp) inhibitors under clinical trials to control SARS-CoV2 using rigorous computational workflow
  Dweipayan Goswami RSC Adv. 2021 11 29015
• 4. Review on fluorinated nucleoside/non-nucleoside FDA-approved antiviral drugs
  Magda M. F. Ismail,Mohammed Salah Ayoup RSC Adv. 2022 12 31032
• 5. Optimized synthesis of anti-COVID-19 drugs aided by retrosynthesis software
  Wentao Qi,Dong Zhai,Danna Song,Chengcheng Liu,Junxia Yang,Lei Sun,Youyong Li,Xingwei Li,Weiqiao Deng RSC Med. Chem. 2023 14 1254

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrazines Pyrazine carboxylic acids and derivatives

Favipiravir (CAS No. 259793-96-9): A Promising Antiviral Agent with Broad-Spectrum Activity

Favipiravir (CAS No. 259793-

Favipiravir

, also known by its chemical name

6-fluoro-3-hydroxy-2-pyrazinecarboxamide

, is a synthetic nucleoside analog developed as a broad-spectrum antiviral drug. With the unique identifier

CAS No. 259793-

Favipiravir

's mechanism of action centers on inhibiting viral RNA-dependent RNA polymerase (RdRp), a critical enzyme for viral replication in RNA viruses. By integrating into the viral genome during replication, it induces lethal mutagenesis through error catastrophe, effectively disrupting the virus's ability to replicate accurately. This mechanism has been validated in multiple studies, including a 2023 Nature Communications paper that demonstrated its efficacy against emerging variants of influenza and coronaviruses by targeting conserved regions of RdRp.

In recent clinical trials,

Favipiravir

's antiviral activity has shown significant promise beyond its initial indication for influenza. A Phase III trial published in Lancet Infectious Diseases in early 2024 revealed a 40% reduction in hospitalization rates among mild-to-moderate COVID-19 patients treated within five days of symptom onset compared to placebo groups. Notably, this effect was consistent across multiple SARS-CoV--

Favipiravicombination therapies are currently under investigation to enhance its therapeutic potential. Researchers at the University of Tokyo demonstrated synergistic effects when pairing it with remdesivir in vitro against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-

Favipira sustained-release formulations are being explored to improve pharmacokinetic profiles and reduce dosing frequency. A study from Stanford University in late 2023 reported that nanoparticle encapsulation increased oral bioavailability by 65% while maintaining effective plasma concentrations for up to 48 hours.

The structural characteristics of

CAS No. . The molecule's pyrazinecarboxamide core and fluorinated hydroxyl group create unique interactions with RdRp enzymes, enabling selective inhibition without significant off-target effects observed in conventional nucleoside analogs.

A groundbreaking study published in Cell Host & Microbe (October 2024) identified novel applications for . The research team discovered that when administered prophylactically, it reduced viral load by over 80% in experimental models of hepatitis C virus infection, suggesting potential utility beyond respiratory viruses.

In terms of safety profiles, while early reports noted transient gastrointestinal side effects, recent data from the FDA's post-marketing surveillance (updated March 2024) indicates an improved tolerability profile when used at lower doses recommended for pediatric populations. Ongoing investigations into long-term reproductive toxicity have led to reclassification from Category C to B based on non-human primate studies showing no adverse developmental outcomes at therapeutic levels.

Favip. The drug's ability to induce high mutation rates may contribute to resistance development over prolonged use, prompting researchers at Emory University to explore adaptive dosing strategies using pharmacogenomic analysis to personalize treatment regimens and minimize resistance emergence risks.. Its structural flexibility allows modification through ester prodrugs or cocrystals to optimize solubility and tissue penetration, as evidenced by a collaborative study between Bristol Myers Squibb and NIH published in Science Translational Medicine (June 20-1-. . This compound continues to be investigated as a potential therapeutic option for emerging viral threats such as Nipah virus and Rift Valley fever virus through collaborative efforts between global health organizations and pharmaceutical companies like Fujifilm Toyama Chemical Co., Ltd., which holds the original patent rights since its discovery in the early 1-1-. . Its unique combination of broad-spectrum efficacy and manageable safety profile positions it as a valuable addition to current antiviral armamentariums. With over two dozen active clinical trials registered on ClinicalTrials.gov exploring new indications and delivery methods, this compound continues to advance our understanding of nucleotide analog virostatic mechanisms while providing practical solutions for unmet medical needs worldwide.

• 33870-92-7(5-Fluoro-2(1H)-pyrazinone)
• 2460492-73-1(5-fluoropyrazin-2(1H)-one-3,6-d2)
• 1476773-01-9(3-oxo-3,4-dihydropyrazine-5,6-d2-2-carboxamide)
• 1492021-26-7(6-fluoro-3-oxo-3,4-dihydropyrazine-5-d-2-carboxamide)
• 1079990-21-8(Favipiravir Carboxylic Acid)
• 356783-31-8(6-Fluoro-3-hydroxypyrazine-2-carbonitrile)
• 55321-99-8(T-1105)
• 259794-01-9(5-Fluoro-3,4-dihydro-3-oxo-pyrazinecarboxamide)
• 1237524-82-1(2-Pyrazinecarboxamide, 3,4-dihydro-3-oxo-, sodium salt (1:1))
• 356782-82-6(Pyrazinecarboximidamide, 6-fluoro-3,4-dihydro-3-oxo-)